title: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
abstract: MicroRNAs are involved in cancer pathogenesis and act as tumor suppressors or oncogenes. It has been recently reported that miR-148a expression is down-regulated in several types of cancer. The functional roles and target genes of miR-148a in prostate cancer, however, remain unknown. In this report, we showed that miR-148a expression levels were lower in PC3 and DU145 hormone-refractory prostate cancer cells in comparison to PrEC normal human prostate epithelial cells and LNCaP hormone-sensitive prostate cancer cells. Transfection with miR-148a precursor inhibited cell growth, and cell migration and invasion, and increased the sensitivity to anti-cancer drug paclitaxel in PC3 cells. Computer-aided algorithms predicted mitogen- and stress-activated protein kinase, MSK1, as a potential target of miR-148a. Indeed, miR-148a overexpression decreased expression of MSK1. Using luciferase reporter assays, we identified MSK1 as a direct target of miR-148a. Suppression of MSK1 expression by siRNA, however, showed little or no effects on malignant phenotypes of PC3 cells. In PC3PR cells, a paclitaxel-resistant cell line established from PC3 cells, miR-148a inhibited cell growth, and cell migration and invasion, and also attenuated the resistance to paclitaxel. MiR-148a reduced MSK1 expression by directly targeting its 3'-UTR in PC3PR cells. Furthermore, MSK1 knockdown reduced paclitaxel-resistance of PC3PR cells, indicating that miR-148a attenuates paclitaxel-resistance of hormone-refractory, drug-resistant PC3PR cells in part by regulating MSK1 expression. Our findings suggest that miR-148a plays multiple roles as a tumor suppressor and can be a promising therapeutic target for hormone-refractory prostate cancer especially for drug-resistant prostate cancer.
authors.affiliation: Department of Longevity and Aging Research, Gifu International Institute of Biotechnology, Kakamigahara, Gifu 504-0838, Japan.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Fujita
authors.forename: Keitaro
authors.initials: K
authors.lastname: Kojima
authors.forename: Riyako
authors.initials: R
authors.lastname: Ohhashi
authors.forename: Nanako
authors.initials: N
authors.lastname: Hamada
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Nozawa
authors.forename: Aya
authors.initials: A
authors.lastname: Kitamoto
authors.forename: Akira
authors.initials: A
authors.lastname: Sato
authors.forename: Shinji
authors.initials: S
authors.lastname: Kondo
authors.forename: Toshio
authors.initials: T
authors.lastname: Kojima
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ito
mesh_terms: D000818:Animals; D001483:Base Sequence; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004847:Epithelial Cells / Q000166:cytology; D006728:Hormones / Q000378:metabolism; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000737:chemistry* / Q000378:metabolism; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019893:Ribosomal Protein S6 Kinases / Q000378:metabolism; D038744:Ribosomal Protein S6 Kinases, 90-kDa / Q000378:metabolism*; D017386:Sequence Homology, Amino Acid
chemical_list: D006728:Hormones; D035683:MicroRNAs; D019893:Ribosomal Protein S6 Kinases; D038744:Ribosomal Protein S6 Kinases, 90-kDa; C116919:mitogen and stress-activated protein kinase 1; D017239:Paclitaxel
references.citation: J Immunol. 2006 Dec 1;177(11):7950-8
references.pmid: 17114467
references.citation: Oncogene. 2003 Feb 6;22(5):746-55
references.pmid: 12569367
references.citation: J Cell Biochem. 2008 Jun 1;104(3):785-94
references.pmid: 18172855
references.citation: Cancer Res. 2002 Jan 1;62(1):75-8
references.pmid: 11782362
references.citation: J Biol Chem. 2001 Aug 31;276(35):33213-9
references.pmid: 11441012
references.citation: Cancer Res. 2008 Apr 1;68(7):2538-47
references.pmid: 18381464
references.citation: BMC Mol Biol. 2003 May 26;4:6
references.pmid: 12769834
references.citation: Int J Oncol. 2009 Feb;34(2):537-42
references.pmid: 19148490
references.citation: J Biol Chem. 2002 Dec 27;277(52):50550-6
references.pmid: 12414794
references.citation: Annu Rev Med. 2009;60:167-79
references.pmid: 19630570
references.citation: J Pathol. 2008 Jan;214(1):17-24
references.pmid: 17948228
references.citation: EMBO J. 2003 Jun 2;22(11):2788-97
references.pmid: 12773393
references.citation: Hepatology. 2009 Aug;50(2):630-7
references.pmid: 19585622
references.citation: Biochem Biophys Res Commun. 2008 Dec 5;377(1):114-9
references.pmid: 18834855
references.citation: Br J Cancer. 2006 Jan 30;94(2):179-83
references.pmid: 16404435
references.citation: Cancer Gene Ther. 2009 Mar;16(3):206-16
references.pmid: 18949015
references.citation: EMBO J. 1998 Aug 3;17(15):4426-41
references.pmid: 9687510
references.citation: Sci China C Life Sci. 2009 Mar;52(3):224-31
references.pmid: 19294347
references.citation: Curr Pharm Des. 2009;15(4):456-62
references.pmid: 19199973
references.citation: Pancreatology. 2009;9(1-2):66-72
references.pmid: 19077456
references.citation: Curr Cancer Drug Targets. 2009 Jun;9(4):572-94
references.pmid: 19519323
references.citation: Mol Cell Biol. 2002 Apr;22(8):2871-81
references.pmid: 11909979
references.citation: Oncogene. 2008 Mar 13;27(12):1788-93
references.pmid: 17891175
references.citation: Oncogene. 2006 Jul 27;25(32):4449-57
references.pmid: 16532028
references.citation: J Invest Dermatol. 2006 Aug;126(8):1784-91
references.pmid: 16543895
references.citation: Mol Cancer. 2006 Jun 19;5:24
references.pmid: 16784538
references.citation: Cancer Res. 2005 Apr 15;65(8):3108-16
references.pmid: 15833840
references.citation: Sci STKE. 2003 Aug 12;2003(195):PE33
references.pmid: 12915720
references.citation: J Biol Chem. 2008 Apr 11;283(15):9674-80
references.pmid: 18268015
references.citation: Cancer Res. 2007 Jul 1;67(13):6130-5
references.pmid: 17616669
references.citation: Cancer Cell Int. 2008 Sep 17;8:13
references.pmid: 18798999
references.citation: Nat Rev Genet. 2008 Feb;9(2):102-14
references.pmid: 18197166
references.citation: J Cell Mol Med. 2008 Sep-Oct;12(5A):1456-65
references.pmid: 18624768
references.citation: RNA. 2008 May;14(5):872-7
references.pmid: 18367714
references.citation: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61
references.pmid: 18768788
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Mol Cell Biochem. 2009 Feb;322(1-2):103-12
references.pmid: 19002563
references.citation: EMBO J. 2003 Mar 17;22(6):1313-24
references.pmid: 12628924
references.citation: J Biol Chem. 2006 May 5;281(18):12521-5
references.pmid: 16517600